KR100469936B1 - 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 - Google Patents
사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물Info
- Publication number
- KR100469936B1 KR100469936B1 KR10-2004-0040894A KR20040040894A KR100469936B1 KR 100469936 B1 KR100469936 B1 KR 100469936B1 KR 20040040894 A KR20040040894 A KR 20040040894A KR 100469936 B1 KR100469936 B1 KR 100469936B1
- Authority
- KR
- South Korea
- Prior art keywords
- sars
- expression vector
- surface expression
- cell surface
- virus antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 241000315672 SARS coronavirus Species 0.000 title abstract 3
- 239000013604 expression vector Substances 0.000 title abstract 3
- 244000005700 microbiome Species 0.000 title abstract 3
- 210000004027 cell Anatomy 0.000 title 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract 2
- 101100059000 Bacillus subtilis (strain 168) capA gene Proteins 0.000 abstract 1
- 101100059011 Bacillus subtilis (strain 168) capB gene Proteins 0.000 abstract 1
- 101100219452 Bacillus subtilis (strain 168) capC gene Proteins 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 101100083407 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) pgsA1 gene Proteins 0.000 abstract 1
- 229940124680 SARS vaccine Drugs 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 101150103033 lpxB gene Proteins 0.000 abstract 1
- 101150076330 pgsA gene Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20030035993 | 2003-06-04 | ||
| KR1020030035993 | 2003-06-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040104936A KR20040104936A (ko) | 2004-12-13 |
| KR100469936B1 true KR100469936B1 (ko) | 2005-02-03 |
Family
ID=36611852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-0040894A KR100469936B1 (ko) | 2003-06-04 | 2004-06-04 | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060140971A1 (ko) |
| EP (1) | EP1629104A4 (ko) |
| JP (1) | JP2006526403A (ko) |
| KR (1) | KR100469936B1 (ko) |
| CN (1) | CN1798844A (ko) |
| AU (1) | AU2004245859B2 (ko) |
| BR (1) | BRPI0411393A (ko) |
| CA (1) | CA2527346A1 (ko) |
| RU (1) | RU2332457C2 (ko) |
| WO (1) | WO2004108937A1 (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100872042B1 (ko) | 2005-09-14 | 2008-12-05 | 주식회사 바이오리더스 | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050079162A (ko) * | 2004-02-04 | 2005-08-09 | 주식회사 바이오리더스 | 파보바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 |
| KR100517114B1 (ko) * | 2005-02-25 | 2005-09-27 | 주식회사 바이오리더스 | 폴리감마글루탐산을 함유하는 면역보강제 조성물 |
| WO2007008904A2 (en) * | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
| KR100782332B1 (ko) * | 2006-01-23 | 2007-12-06 | 주식회사 바이오리더스 | 새우 흰 반점 바이러스 항원의 표면 발현벡터 및 이에 의해형질전환된 미생물 |
| WO2009038194A1 (ja) * | 2007-09-20 | 2009-03-26 | Kao Corporation | 組換え微生物及びポリ－ガンマ－グルタミン酸の製造方法 |
| JP2014210747A (ja) | 2013-04-19 | 2014-11-13 | アンジェスＭｇ株式会社 | 細胞性免疫誘導能が改善された経口ワクチン |
| CN107428844A (zh) * | 2015-03-05 | 2017-12-01 | 发展生物工程与基因技术的彼得和特劳德尔·恩格尔霍恩基金会 | 用于将肽呈递在细胞表面上的系统 |
| RU2639246C1 (ru) * | 2016-12-21 | 2017-12-20 | Федеральное государственное бюджетное учреждение "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ГосНИИгенетика) | Применение домена белка S-слоя из Lactobacillus brevis в качестве компонента системы для экспонирования слитых белков на поверхности клеток молочнокислых бактерий |
| EP3940077A4 (en) * | 2018-10-10 | 2022-08-10 | Bioleaders Corporation | SURFACE EXPRESSION VECTOR WITH TWO KINDS OF PROMOTERS FROM LACTOBACILLUS CASEI FOR SIMULTANEOUS EXPRESSION OF TWO TARGET PROTEINS AND METHODS FOR EXPRESSING PROTEINS ON A MICROBIAL SURFACE USING THE SAME |
| WO2021147025A1 (en) * | 2020-01-22 | 2021-07-29 | The University Of Hong Kong-Shenzhen Hospital | Anti 2019-ncov vaccine |
| CN112877351A (zh) * | 2020-04-14 | 2021-06-01 | 文利新 | 一种用于防治新冠病毒感染的重组质粒、重组乳酸杆菌表达系统及其应用 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| AU2021294342A1 (en) * | 2020-06-26 | 2023-02-23 | Elicio Therapeutics, Inc. | Compositions and methods for inducing an immune response against coronavirus |
| CN112760336A (zh) * | 2020-12-30 | 2021-05-07 | 广州辉园苑医药科技有限公司 | 一种抗原表位肽的表达系统和表面展示系统及它们的构建方法 |
| JPWO2022163647A1 (ko) * | 2021-01-26 | 2022-08-04 | ||
| KR20220125776A (ko) | 2021-03-07 | 2022-09-14 | 오영운 | 돼지갈비 포의 가공 및 분류방법 |
| WO2023022973A2 (en) * | 2021-08-16 | 2023-02-23 | Elicio Therapeutics, Inc. | Compositions containing polynucleotide amphiphiles and methods of use thereof |
| WO2023044327A1 (en) * | 2021-09-15 | 2023-03-23 | Colorado State University Research Foundation | Recombinant vaccine compositions |
| CN113755421B (zh) * | 2021-09-28 | 2024-04-12 | 梦芊细胞因子有限公司 | 一种用于covid-19的口服性疫苗及抗体加强剂 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001017182A (ja) * | 1999-07-09 | 2001-01-23 | Nagase & Co Ltd | ポリ−γ−グルタミン酸の製造方法 |
| ATE342990T1 (de) * | 2001-08-10 | 2006-11-15 | Bioleaders Corp | Oberflächenexpressionsvektoren mit pgsbca, dem für poly-gamma-glutamat-synthetase codierenden gen, sowie verfahren zur expression eines zielproteins an der oberfläche eines den vektor benutzenden mikroorganismus |
| JP4549858B2 (ja) * | 2002-10-17 | 2010-09-22 | バイオリーダーズ コーポレイション | ヒト・パピローマウイルスに対するワクチン用ベクターおよび同ベクターによって形質転換された微生物 |
| WO2005035556A2 (en) * | 2003-05-06 | 2005-04-21 | Iguazu Biosciences Corp. | Sars-coronavirus virus-like particles and methods of use |
-
2004
- 2004-06-04 AU AU2004245859A patent/AU2004245859B2/en not_active Ceased
- 2004-06-04 BR BRPI0411393-4A patent/BRPI0411393A/pt not_active IP Right Cessation
- 2004-06-04 JP JP2006508539A patent/JP2006526403A/ja active Pending
- 2004-06-04 CN CNA2004800152757A patent/CN1798844A/zh active Pending
- 2004-06-04 WO PCT/KR2004/001341 patent/WO2004108937A1/en active Application Filing
- 2004-06-04 EP EP04736153A patent/EP1629104A4/en not_active Withdrawn
- 2004-06-04 RU RU2005141528/13A patent/RU2332457C2/ru not_active IP Right Cessation
- 2004-06-04 US US10/559,631 patent/US20060140971A1/en not_active Abandoned
- 2004-06-04 KR KR10-2004-0040894A patent/KR100469936B1/ko not_active IP Right Cessation
- 2004-06-04 CA CA002527346A patent/CA2527346A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100872042B1 (ko) | 2005-09-14 | 2008-12-05 | 주식회사 바이오리더스 | 마이오스타틴을 발현하는 세포표면 발현벡터 및 상기벡터에 의해 형질전환된 미생물 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1629104A1 (en) | 2006-03-01 |
| KR20040104936A (ko) | 2004-12-13 |
| RU2005141528A (ru) | 2006-06-27 |
| BRPI0411393A (pt) | 2006-08-01 |
| AU2004245859B2 (en) | 2007-02-08 |
| CA2527346A1 (en) | 2004-12-16 |
| EP1629104A4 (en) | 2006-11-02 |
| RU2332457C2 (ru) | 2008-08-27 |
| US20060140971A1 (en) | 2006-06-29 |
| WO2004108937A1 (en) | 2004-12-16 |
| JP2006526403A (ja) | 2006-11-24 |
| AU2004245859A1 (en) | 2004-12-16 |
| CN1798844A (zh) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100469936B1 (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
| AU2001243259A1 (en) | Genes encoding denitrification enzymes | |
| CY1106334T1 (el) | Βελτιστοποιημενου κωδικονιου αλληλουχιες ιου θηλωματος | |
| HK1109421A1 (en) | Chimeric adenoviruses for use in cancer treatment | |
| GB0326798D0 (en) | Methods for generating mutant virus | |
| WO2005059093A3 (de) | P ef-tu-expressionseinheiten | |
| NZ597601A (en) | Treatment and prevention of influenza | |
| WO2003080807A3 (en) | Compositions and methods for suppressing eukaryotic gene expression | |
| WO2010122367A3 (en) | Meganuclease variants cleaving the genomic insertion of a virus and uses thereof | |
| SG156690A1 (en) | Mammalian genes involved in infection | |
| EP1712243A4 (en) | GENE THERAPY FOR TUMOR USING A NEGATIVE CHAIN RNA VIRAL VECTOR ENCODING AN IMMUNOSTIMULATORY CYTOKINE | |
| MX2007009628A (es) | Virus de acido ribonucleico en replicacion como vacunas. | |
| WO2020127532A3 (en) | Rna encoding a protein | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| BRPI0518109A (pt) | cepa bacteriana, nucleocapsìdeo, preparação de vacina, método para criar uma bactéria recombinante, bactéria mutante, seqüências de rna fluorado para deslanchar rdsrna e meio para eletroporação | |
| WO2008133137A1 (ja) | 遺伝子治療のためのベクター | |
| AU8491401A (en) | Phage-dependent superproduction of biologically active protein and peptides | |
| TNSN07090A1 (en) | Novel laccase enzyme and use thereof | |
| DK1481052T3 (da) | Hyaluronan-syntase-gener og ekspression deraf | |
| EP2434018A3 (en) | A novel beta-galactoside-alpha2, 3-sialyltransferase, a gene encoding thereof, and a method for producing thereof | |
| UA90098C2 (en) | Promoter of vaccinia virus | |
| WO2004018630A3 (en) | Recombinant double-stranded rna phages and uses thereof | |
| EP1149917A3 (en) | Hepatitis B virus vectors for gene therapy | |
| TW200617162A (en) | Surface display vector of sars virus antigen and microorganisms transformed thereby | |
| WO2001072977A3 (en) | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130128 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140127 Year of fee payment: 10 |
|
| LAPS | Lapse due to unpaid annual fee |